96
Participants
Start Date
December 18, 2014
Primary Completion Date
January 21, 2020
Study Completion Date
January 21, 2020
Atezolizumab
During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.
Obinutuzumab
During safety evaluation stage, obinutuzumab will be administered as 1000 mg IV infusion. During expansion stage, obinutuzumab will be administered as either 1000 mg IV infusion or at dose decided from safety evaluation stage.
Tazemetostat
Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21.
Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin
University of North Carolina at Chapel Hill, Chapel Hill
Hopital Saint Eloi, Montpellier
Fort Wayne Neurological Center, Fort Wayne
Hopital Claude Huriez - CHU Lille; Service des maladies du sang, Lille
Centre Hospitalier Lyon Sud, Pierre-Bénite
Hôpital Saint-Louis, Paris
MD Anderson Cancer Center, Houston
Universitaetsklinikum Freiburg, Freiburg im Breisgau
City of Hope National Medical Center, Duarte
Institut Gustave Roussy, Villejuif
UW- Fred Hutchinson Cancer Center, Seattle
Hackensack University Medical Center, Hackensack
Sloan Kettering Cancer Center, New York
Barts Hospital, London
Hoffmann-La Roche
INDUSTRY